Trials / Conditions / High Risk Acute Myeloid Leukemia

High Risk Acute Myeloid Leukemia

13 registered clinical trials studyying High Risk Acute Myeloid Leukemia — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT NCT07183878	First Affiliated Hospital of Zhejiang University	N/A
Recruiting	Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogenei NCT07237230	Donghua Zhang	N/A
Recruiting	Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HS NCT06839456	Children's Hospital of Philadelphia	Phase 1 / Phase 2
Not Yet Recruiting	Effect of Donor Chose on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG/PTCy for Hap NCT06686173	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	—
Recruiting	Novel Digital Application for Patients With Acute Leukemia NCT06472128	Massachusetts General Hospital	N/A
Recruiting	Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients NCT06394011	The First Affiliated Hospital of Soochow University	Phase 2
Recruiting	Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia NCT05237258	Massachusetts General Hospital	N/A
Unknown	Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT NCT05066958	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Phase 1 / Phase 2
Withdrawn	QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML NCT03365661	Masonic Cancer Center, University of Minnesota	Phase 2
Active Not Recruiting	Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer U NCT02861417	M.D. Anderson Cancer Center	Phase 2
Unknown	CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML NCT03384212	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Phase 3
Unknown	CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractor NCT03384225	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Phase 3
Completed	Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute M NCT01696084	Jazz Pharmaceuticals	Phase 3